XOMA (NASDAQ:XOMA) Issues Quarterly Earnings Results

XOMA (NASDAQ:XOMA) announced its quarterly earnings results on Tuesday. The biotechnology company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.07, Bloomberg Earnings reports. XOMA had a negative return on equity of 51.66% and a negative net margin of 48.62%. The company had revenue of $0.96 million for the quarter, compared to the consensus estimate of $0.63 million.

Shares of XOMA stock traded up $0.22 during midday trading on Wednesday, hitting $16.21. The company had a trading volume of 448 shares, compared to its average volume of 72,217. The company’s 50 day moving average price is $17.17. The company has a market cap of $136.21 million, a PE ratio of -10.18 and a beta of 1.29. The company has a current ratio of 7.20, a quick ratio of 7.20 and a debt-to-equity ratio of 1.13. XOMA has a 1-year low of $11.02 and a 1-year high of $24.66.

In related news, major shareholder Bvf Partners L. P/Il acquired 10,300 shares of the stock in a transaction dated Friday, May 10th. The shares were acquired at an average price of $14.57 per share, for a total transaction of $150,071.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Bvf Partners L. P/Il acquired 3,797 shares of the stock in a transaction dated Monday, May 13th. The stock was bought at an average price of $14.36 per share, for a total transaction of $54,524.92. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 42,010 shares of company stock worth $612,963. 9.89% of the stock is currently owned by corporate insiders.

Several equities analysts have commented on XOMA shares. Wedbush reiterated a “buy” rating and set a $25.00 price target on shares of XOMA in a report on Wednesday. HC Wainwright set a $30.00 price target on XOMA and gave the company a “buy” rating in a report on Friday, June 14th. Finally, ValuEngine downgraded XOMA from a “buy” rating to a “hold” rating in a report on Tuesday. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $23.75.

XOMA Company Profile

XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy.

Further Reading: What is an Initial Public Offering (IPO)?

Earnings History for XOMA (NASDAQ:XOMA)

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.